CoChat

Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation

Open access
Ameri, Hossein · 2018 · Journal of Current Ophthalmology
Cited by 70

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutationThe approval of voretigene neparvovec-rzyl by the US Food and Drug Administration (FDA), in December 2017, marked the beginning of a new era in medicine in which many inherited diseases will be essentially corrected by gene therapy.Voretigene neparvovec-rzyl, with the trade name of Luxturna, is the first gene therapy for an inherited disease.It is intended for the treatment of RPE65 mutation-associated retinal dystrophy, making it the second commercially available treatment for inherited retinal disease (IRD) after retinal prostheses (Argus II and Alpha IMS) which were commercialized a few years earlier.Unlike retinal prostheses, voretigene neparvovec-rzyl modifies the course of the disease.Voretigene neparvovec-rzyl is composed of human RPE65 cDNA along with a cytomegalovirus enhancer and a hybrid chicken b-actin promoter incorporated into a recombinant adeno-associated virus 2 (AAV2).Following injection into the subretinal space, AAV2 enters retinal pigment epithelial (RPE) cells.While the viral vector remains in episomal form in the nucleus, without integrating into the host DNA, the enhancer and promoter facilitate expression of RPE65.Retinitis pigmentosa (RP) is the most common IRD, and Leber's congenital amaurosis (LCA) is a severe form of IRD presenting at birth or childhood.Affected patients present with nyctalopia and peripheral visual field defect followed by central vision loss in advanced stages of the disease.Currently, mutations in approximately 300 genes are known to cause IRD.Mutations in RPE65 account for approximately 2% of autosomal recessive RP and 16% of LCA. 1 Although an uncommon cause of IRD, several factors have made RPE65 a favorite target for gene therapy: 1) It causes autosomal recessive IRD, in which gene replacement is sufficient to treat the disease.2) About two decades ago, when gene delivery methods were being developed, RPE65 was one of only over a dozen genes that were known to cause IRD. 3) The relatively small size of RPE65 gene makes it possible to be carried by AAV2.4) The clinical course of LCA in which photoreceptor Peer review under responsibility of the Iranian Society of Ophthalmology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.joco.2018.01.006

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Ameri, H.
Venue
Journal of Current Ophthalmology
Publisher
Medknow
Published
2018-03
Volume
30
Issue
1
Pages
1-2
ISSN
2452-2325 (ISSN-L)
OpenAlex
W2793446133
Cited by
70
References
7
FWCI
2.98
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.